Rhopressa (netarsudil) / Alcon - LARVOL DELTA

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

Initial efficacy results of Latanoprost 0.005% + Netarsudil 0.02% combination drops, from a single centre (EVER 2025) - No abstract available

Clinical • Ophthalmology

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Massachusetts Eye and Ear Infirmary | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Sep 2026

Enrollment open • Trial completion date • Trial primary completion date • Retinal Disorders

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Westlake Eye Specialists | Trial completion date: Dec 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Conjunctival histopathological changes associated with netarsudil 0.02. (PubMed, Eye (Lond)) - "Conjunctiva treated with netarsudil may be more likely to demonstrate inflammation compared to those treated with other combinations of glaucoma medications. These findings may have surgical implications and additional studies correlating clinical outcomes are required."

Journal • Glaucoma • Inflammation • Ophthalmology

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma (clinicaltrials.gov) - P4 | N=35 | Not yet recruiting | Sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

New P4 trial • Glaucoma • Ophthalmology

RhoKinase (ROCK) Inhibition as a Therapeutic Strategy for Pseudophakic Bullous Keratopathy: A Comprehensive Review. (PubMed, J Clin Med) - "ROCK inhibitors represent a novel pharmacological strategy for PBK prevention and management, potentially reducing dependency on donor grafts. Further research is needed to determine long-term safety, optimal dosing, and efficacy."

Journal • Review • Cataract • Ophthalmology • Pain • Transplant Rejection • Transplantation

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Recruiting | Sponsor: Alcon Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Intraocular Pressure Equations Utilizing Aqueous Fluid Flow and Flow Facility in the Steady-State and Time-Dependent Domains. (PubMed, Clin Ophthalmol) - "The steady-state equation was validated by replicating the results of a published IOP efficacy study of combined netarsudil and latanoprost treatment results with a 3% error. Enhanced IOP equations provide a novel framework for modeling IOP dynamics. Potential applications include understanding IOP pathophysiology, evaluating therapeutic interventions, and predicting temporal/diurnal IOP fluctuations."

Journal • Cardiovascular • CNS Disorders • Glaucoma • Ophthalmology

A Comprehensive Review of the Role of Rho-Kinase Inhibitors in Corneal Diseases. (PubMed, Life (Basel)) - "ROCKI, such as ripasudil and netarsudil, enhances endothelial cell migration, and promotes repair in conditions characterized by endothelial dysfunction. This narrative review provides a comprehensive evaluation of ROCKI's mechanism of action, pharmacological properties, safety profile, applications in corneal disease management, emerging clinical trials, and novel approaches. We emphasize both preclinical and clinical findings, highlight existing evidence gaps, and outline future research priorities."

Journal • Review • Cataract • Inflammation • Ophthalmology • Transplantation

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (clinicaltrials.gov) - P3 | N=470 | Not yet recruiting | Sponsor: Alcon Research

New P3 trial • Cardiovascular • Glaucoma • Ophthalmology

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Westlake Eye Specialists | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Therapeutic Potential of Rho Kinase Inhibitors in Corneal Disease: A Systematic Review of Preclinical and Clinical Studies. (PubMed, Biomedicines) - "Preclinical models (rabbit, porcine, human explants) uniformly showed ROCKis (Y-27632, Ripasudil, Netarsudil, H-1152) accelerate corneal endothelial cell proliferation, migration, and restoration of a hexagonal monolayer with improved barrier and pump function over days to weeks. ROCKis demonstrate consistent pro-regenerative effects on corneal endothelium in multiple models and show promising clinical efficacy in Fuchs endothelial dystrophy and pseudophakic endothelial failure. Future work should explore novel delivery systems and larger controlled trials to optimize dosing, safety, and long-term outcomes."

Journal • Preclinical • Review • Ophthalmology

Comparison of Dorzolamide and Netarsudil on Intraocular Pressure and Ocular Perfusion in Early Glaucoma: A Randomized Controlled Trial. (PubMed, J Glaucoma) - "Netarsudil causes an increase in all the OCTA parameters - mVD, ONH perfusion, and ONH FI whereas Dorzolamide causes an increase only in ONH perfusion in preperimetric/early glaucoma patients. Netarsudil monotherapy also showed a higher decrease in IOP as compared to dorzolamide therapy."

Journal • Glaucoma • Ophthalmology

Netarsudil-associated Reticular Bullous Corneal Epithelial Edema in a Bullous Keratopathy Patient with Glaucoma. (PubMed, Korean J Ophthalmol) - No abstract available

Journal • Glaucoma • Ophthalmology

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) (clinicaltrials.gov) - P4 | N=68 | Not yet recruiting | Sponsor: Center for Sight Las Vegas

New P4 trial • Glaucoma • Ophthalmology

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: East Coast Institute for Research | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Rho kinase inhibitors: a patent review (2017 - 2023). (PubMed, Expert Opin Ther Pat) - "Fasudil, ripasudil, netarsudil, and belumosudil are the primary ROCK inhibitors approved for human use. Despite some pharmacokinetic challenges, research in this field continues to advance, with significant potential for further clinical development."

Journal • Review

Retrospective analysis of the influence of prior treatment type on tolerability characteristics of NET/LAT and BIM/TIM using data from the MERCURY 3 study in patients with open-angle glaucoma and OHT (SOE 2025) - "Purpose: A post hoc analysis compared the tolerability characteristics of netarsudil 0.02%/latanoprost 0.005% (NET/LAT) and bimatoprost 0.03%/timolol 0.5% (BIM/TIM) in patients with glaucoma or ocular hypertension (OHT), stratified by either prior IOP-lowering monotherapy (pM) or combination therapy (pCT) before enrolment. MERCURY-3 study data were analysed retrospectively for the rate of treatment-emergent adverse events (TEAEs) and withdrawals due to adverse events (AEs), as well as the incidence of conjunctival hyperaemia (CH) and corneal verticillata (CV). NET/LAT pts with pM had a somewhat lower incidence of overall TEAEs and of CH, compared with those with pCT. This might contribute to a statistically significantly lower AE-attributed withdrawals. The results suggest that more complex or aggressive IOP-lowering therapy before the introduction of NET/LAT may be causally related to the incidence of clinically significant TEAEs in glaucoma and ocular hypertensive..."

Retrospective data • Glaucoma • Ophthalmology

Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors). (PubMed, Int Ophthalmol) - "Topical netarsudil 0.02% once daily was well tolerated with fewer side effects and in reducing IOP than topical ripasudil 0.4% twice daily dosing in POAG patients. Netarsudil 0.02% once daily may be considered an important option for the IOP control in POAG."

Clinical • Journal • Glaucoma • Ophthalmology • Pain

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy (clinicaltrials.gov) - P=N/A | N=50 | Enrolling by invitation | Sponsor: University Hospital Dubrava

New trial • Cataract • Glaucoma • Ophthalmology • Transplantation

The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bulbous Keratopathy (PBK) (clinicaltrials.gov) - P=N/A | N=50 | Enrolling by invitation | Sponsor: University Hospital Dubrava

New trial • Glaucoma • Ophthalmology

Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety. (PubMed, J Med Chem) - "D25 potently inhibited ROCK1/2 with IC50 values of 47.2 nM and 33.8 nM, respectively, surpassing Netarsudil...R3 exhibited weaker IOP-lowering efficacy but better selectivity. D25 is a promising glaucoma treatment candidate, with R3 as a safer alternative for further optimization."

Journal • Preclinical • Glaucoma • Ophthalmology

Rho Kinase (ROCK) Inhibitors in the Treatment of Glaucoma and Glaucoma Surgery: A Systematic Review of Early to Late Phase Clinical Trials. (PubMed, Pharmaceuticals (Basel)) - " A systematic database search was conducted in Ovid MEDLINE and Ovid Embase on 5 April 2022 using the following keywords: 'glaucoma', 'rho kinase inhibitor', 'rho-kinase inhibitor', 'rock inhibitor', 'ripasudil', 'netarsudil', and 'fasudil'. To elucidate their long-term therapeutic value and safety comprehensively, further independent, large-scale, prospective randomized controlled trials are warranted. Such studies are pivotal to augment our understanding of this emergent medication class."

Journal • Review • Cardiovascular • Glaucoma • Immunology • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Drugs for open-angle glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology